Affiliation:
1. Siberian State Medical University (SSMU)
2. Medical Сenter “Siberian Doctor”
3. Research Institute Cardiology, Tomsk National Research Medical Center (TNRMC) of Russian Academy of Sciences (RAS)
Abstract
Taking into account the increase in the level of cardiovascular diseases in recent decades, the clinician faces the task of attempting to make the fastest possible diagnosis of the pathology at its earliest stages. That is why the aim of our work was to identify the main groups of biological markers, and to separate the role of each of them in the assessment of the risk of development, progression and possible complications of cardiovascular diseases. We have given the main working classification of markers of cardiovascular processes with the allocation of their main types, as well as the basic criteria for the “ideal” biological marker. Finally, an attempt was made to structure biomarkers depending on their molecular mechanisms of pathogenesis in the development of a particular pathology. All these data should help the clinician at the stage of early diagnosis of cardiovascular disease.
Publisher
Siberian State Medical University
Reference53 articles.
1. Kalyuzhin V.V., Teplyakov A.T., Solovtsov M.A., Kalyuzhina E.V., Bespalova I.D., Terentyeva N.N. Remodeling of the left ventricle: one or several scenarios? Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2016; 15 (4): 120–139 (in Russ.). DOI: 10.20538/1682-0363-2016-4-120-139.
2. Kalyuzhin V.V., Teplyakov A.T., Kalyuzhin O.V. Heartfailure. Мoscow: Medicinskoe informacionnoe agentstvo Publ., 2018: 376 (in Russ.).
3. Berezin A.E.. Biological markers of cardiovascular disease. Guide for doctors: In 3 parts. Kiev: Morion Publ., 2014. Part 1: 652 (in Russ.).
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69 (3): 89–95. DOI: 10.1067/mcp.2001.113989.
5. Colburn W.A. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J. Clin. Pharmacol. 2000; 40 (12 Pt. 2): 1419–1427.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献